...
首页> 外文期刊>Diabetes therapy >The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus
【24h】

The Role of Dyslipidemia Control in the Progression of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus

机译:血脂异常控制在2型糖尿病患者糖尿病性视网膜病变进展中的作用

获取原文
           

摘要

Diabetic retinopathy (DR) is a common microvascular complication of diabetes mellitus (DM) and is considered as the leading cause of visual impairment in working-aged adults worldwide. Dyslipidemia has been associated with DR, but not with progression to the proliferative form of DR, although the exact role in the pathogenesis of DR and diabetic macular edema (DME) remains controversial. As a result, a reasonable question arising is whether control of dyslipidemia may alter the course of DR. Statins do not appear to have an impact on DR progression. On the other hand, fenofibrate has been found to significantly reduce the rate of progression of DR in patients with pre-existing mild DR, although it has no impact on patient’s vision nor on the prevention of DR development in patients with type 2 DM without DR. An interesting point that needs further evaluation is why patients without DR or those with severe DR appear to have no benefit from fenofibrate treatment.
机译:糖尿病性视网膜病(DR)是糖尿病(DM)的常见微血管并发症,被认为是全球工作年龄成年人视力障碍的主要原因。血脂异常与DR相关,但与DR增生形式无关,尽管在DR和糖尿病性黄斑水肿(DME)发病机理中的确切作用仍然存在争议。结果,出现一个合理的问题是血脂异常的控制是否会改变DR的病程。他汀类药物似乎对DR进展没有影响。另一方面,已发现非诺贝特可显着降低既往患有轻度DR的患者的DR病情发展速度,尽管它对无视力的2型DM患者的视力或预防DR的发展均无影响。一个需要进一步评估的有趣观点是,为什么没有DR或患有严重DR的患者似乎无法从非诺贝特治疗中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号